Document is current
Any future updates will be listed below
-
Authors
Giovannetti, Ambra Mara https://orcid.org/0000-0002-7496-6727
Rosato, Rosalba https://orcid.org/0000-0002-4921-374X
Galán, Ingrid https://orcid.org/0000-0001-5774-4260
Toscano, Anna https://orcid.org/0000-0002-2675-2257
Anglada, Elisenda https://orcid.org/0000-0001-5074-4970
Menendez, Rebeca
Hoyer, Jürgen https://orcid.org/0000-0002-1697-6732
Confalonieri, Paolo https://orcid.org/0000-0001-8030-5725
Giordano, Andrea https://orcid.org/0000-0003-4466-9788
Pakenham, Kenneth Ian https://orcid.org/0000-0002-8653-4593
Pöttgen, Jana https://orcid.org/0000-0002-6665-2154
Solari, Alessandra https://orcid.org/0000-0001-9930-7579
-
Funding
Funding for this research was provided by:
Rehabilitation in multiple sclerosis (RIMS GRANT PROGRAM 2018)
- License Information
-
More Information
Article History
Accepted: 15 January 2024
First Online: 24 February 2024
Declarations
:
: AS reports grants from Fondazione Italiana Sclerosi Multipla (FISM) while conducting the study; AS reports personal fees from Biogen Idec, Merck Serono, Novartis, Almirall, and Excemed. JP reports grants from Merck Serono and BMS Celgene.
: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committees of the three enrolling centres: FINCB (12/09/2018, internal ref: 54; first amendment approved 12/12/2018, internal ref: 57; second amendment approved 08/05/2019, internal ref: 62), UKE (23/04/2019, clearance number: PV6040), and Cemcat (01/03/2019, clearance number: PR(AG)29/2019).
: Informed consent was obtained from all individual participants included in the study.
